NIH Study Keeps Synairgen’s Dream Of An Inhaled COVID-19 Therapy Alive
Two Readouts Expected In 2022
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.